Arch Therapeutics Announces Collaboration With University College Cork School of Pharmacy
July 22, 2014 08:30 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 22, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, has entered into a new...
Arch Therapeutics Selects BSI as Its European Union Notified Body
July 15, 2014 08:30 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 15, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Appoints Richard Davis as Chief Financial Officer
July 07, 2014 18:06 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jul 7, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23
June 16, 2014 08:15 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jun 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Inc. to Present at the LD MICRO Invitational 2014 on June 4th
May 28, 2014 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - May 28, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Inc. to Present at the Third Annual Marcum MicroCap Conference
May 27, 2014 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - May 27, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering and Quality Systems and Peter LaCrosse as Chief of Staff
April 01, 2014 08:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Apr 1, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March
March 26, 2014 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Mar 26, 2014) - Rutledge Ellis-Behnke, PhD, co-founder and inventing scientist at Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company"), a life sciences...
Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
February 26, 2014 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 26, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
Arch Therapeutics Secures $2.85 Million Private Placement
February 10, 2014 09:00 ET
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 10, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...